Phospho-MAP Kinase Whole Cell Lysate Set

Related Publications	Journal	Year

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. Spitzer, P., Scheib, H., Kamrowski-Kruck, H, Otto, M., Chiasserini, D., Parnetti, L., Herukka, S.K., Schuchhart, J., Wiltfang, J., Klafki, H.W.	International Journal of Alzheimer's Disease.	2011
Structural details and composition of Trichomonas vaginalis lipophosphoglycan in relevance to the epithelial immune function. Singh, B.N., Hayes, G.R., Lucas, J.J., Sommer, U., Viseux, N., Mirgorodskaya, E., Trifonova, R.T., Sassi, R.R., Costello, C.E., Fichorova, R.N.	Glycoconj J.	2009
Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells. Grund, E.M., Kagan, D., Tran, C.A., Zeitvogel, A., Starzinski-Powitz, A., Nataraja, S., Palmer, S.S.	Mol Pharmacol.	2008
Measurement of ERK 1/2 in CSF from Patients with Neuropsychiatric Disorders and Evidence for the Presence of the Activated Form. Klafki, H.W., Lewczuk, P., Kamrowski-Kruck, H., Maler, J.M., Müller, K., Peters, O., Heuser, I., Jessen, F., Popp, J., Frölich, L., Wolf, S., Prinz, B., Luckhaus, C., Schröder, J., Pantel, J., Gertz, H.J., Kölsch, H., Müller, B.W., Esselmann, H., Bibl, M., Kornhuber, J., Wiltfang, J.	Alzheimers Dis.	2009
In Vivo and In Vitro Characterization of a First-in-Class Novel Azole Analog That Targets Pregnane X Receptor Activation. Venkatesh, M., Wang, H., Cayer, J., Leroux, M., Salvail, D., Das, B., Wrobel, J.E., Mani, S.	Mol Pharmacol.	2011
Selective and potent raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Carnahan, J., Beltran, P.J., Babij, C., Le, Q., Rose, M.J., Vonderfecht, S., Kim, J.L., Smith, A.L., Nagapudi, K., Broome, M.A., Fernando, M., Kha, H., Belmontes, B., Radinsky, R., Kendall, R., Burgess, T.L.	Mol Cancer Ther.	2010
ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFalpha release. Hua, F., Henstock, P.V., Tang, B.	Int Immunopharmacol.	2010
Chronic treatment with epoxyeicosatrienoic acids modulates insulin signaling and prevents insulin resistance in hepatocytes. Skepner, J.E., Shelley, L.D., Ji, C., Reidich, B., Luo, Y.	Prostaglandins &Other Lipid Mediators.	2010
p38 mitogen-activated protein kinase targets the production of proinflammatory endothelial microparticles. Curtis, A.M., Wilkinson, P.F., Gui, M., Gales, T.L, Hu, E., Edelberg, J.M.	J Thromb Haemost.	2009
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin resistant mouse models-Association with liver and adipose tissue effects. Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y.Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.C., Graham, M., Busby, J., Hecht, R., Li, Y.S., Li, Y., Lindberg, R.A., Véniant, M.M.	Am J Physiol Endocrinol Metab.	2009
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Angell, R.M., Angell, T.D., Bamborough, P., Bamford, M.J., Chung, C.W., Cockerill, S.G., Flack, S.S., Jones K.L., Laine, D.I., Longstaff, T., Ludbrook, S., Pearson, R., Smith. K.J., Smee, P.A., Somers, D.O., Walker, A.L.	Bioorg Med Chem Lett	2008
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models. Brake, R., Starnes, C., Lu, J., Chen, D., Yang, S., Radinsky, R., Borges, L.	Mol Cancer Res.	2008
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. Dahut, W. L., Scripture, C., Posadas, E., Jain, L., Gulley, J. L., Arlen, P.M., Wright, J.J., Yu, Y., Cao L., Steinberg, S.M., Aragon-Ching, J.B., Venitz, J., Jones, E., Chen, C.C., Figg, W. D.	Clin Cancer Res.	2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Eccles, S.A., Massey, A., Raynaud, F.I., Sharp, S.Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., Aherne, W., Rowlands, M., Hayes, A., Martins, V., Urban, F., Boxall, K., Prodromou, C., Pearl, L., James, K., Matthews, T.P., Cheung, K.M., Kalusa, A., Jones, K., McDonald, E., Barril, X., Brough, P.A., Cansfield, J.E., Dymock, B., Drysdale, M.J., Finch, H., Howes, R., Hubbard, R.E., Surgenor, A., Webb, P., Wood, M., Wright, L., Workman, P.	Cancer Res.	2008
Analysis of mechanistic pathway models in drug discovery: p38 pathway. Hendriks, B.S, Hua, F., Chabot, J.R.	Biotechnol Prog.	2008
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Khakoo, A.Y., Pati, S., Anderson, S.A., Reid, W., Elshal, M.F., Rovira, I.I., Nguyen, A.T., Malide, D., Combs, C.A., Hall, G., Zhang, J., Raffeld, M., Rogers, T.B., Stetler-Stevenson, W., Frank, J.A., Reitz. M., Finkel, T.	J Exp Med.	2006
Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. Bielen A, Box G, Perryman L, Bjerke L, Popov S, Jamin Y, Jury A, Valenti M, Brandon Ade H, Martins V, Romanet V, Jeay S, Raynaud FI, Hofmann F, Robinson SP, Eccles SA, Jones C.	Proc Natl Acad Sci U S A.	2012
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model. Sharma J, Lv H, Gallo JM.	J Pharm Sci.	2012
Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. Gurley SN, Abidi AH, Allison P, Guan P, Duntsch C, Robertson JH, Kosanke SD, Keir ST, Bigner DD, Elberger AJ, Moore BM 2nd.	J Neurooncol.	2012
Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes Hecht R, Li Y, Sun J, Belouski E, Hall M, Hager T, Yie J, Wang W, Winters D, Smith S, Spahr C, Tam L, Shen Z, Stanislaus S, Chinookoswong N, Lau Y, Sickmier A, Michaels ML, Boone T, Veniant MM, Xu J.	PLoS One	2012